Recent insight on improving the iron chelation efficacy of deferasirox by adjuvant therapy in transfusion dependent beta thalassemia children with sluggish response

References

• Aessopos A, Farmakis D, Berdoukas V. Cardiac failure inβ-thalassemia: diagnosis, prevention, and management.thalassemia reports 2011 Dec;1(1):59-65.
   Google Scholar
• Sridharan K, Sivaramakrishnan G. Efficacy and safety of iron chelators in thalassemia and sickle cell disease: A multiple treatment comparison network meta-analysis and trial sequential analysis. Expert Rev Clin Pharmacol. 2018;11(6):1–10.
   Google Scholar
• Lu M-Y, Wang N, Wu W-H, et al. Simultaneous determination of plasma deferasirox and deferasirox-iron complex using an HPLC-UV  system and pharmacokinetics of deferasirox in patients with β-thalassemia major: once-daily versus twice-daily administration. Clin Ther. 2015;37(8):1751–1760.
   Google Scholar
• Shirley M, Plosker GL. Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia. Drugs. 2014;74(9):1017–1027.
   Google Scholar
• Allegra S, De Francia S, Cusato J, et al. Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. Pharmacogenomics. 2017;18(6):539–554.
   Google Scholar
• Hagag AA, Elfrargy MS, Gazar RA et al. Mediterranean Journal Of Hematology and Infectious Diseases 2013;5(1):e2013065. doi:10.4084/mjhid.2013.065
   Google Scholar
• Musallam KM. Managing unresponsiveness or intolerance to deferasirox therapy: a tale of two doses. Expert Rev Hematol. 2011; 4(4):411–414.
   Google Scholar
• Olivieri NF, Sabouhanian A, Gallie BL. Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox. PloS One. 2019;14(2):e0211942.
   Google Scholar
• Hatlebakk J, Katz PO, Camacho-Lobato L, et al. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000;14(10):1267–1272.
   Google Scholar
• Pomeranze J, Lucarello RJ. Tocopherol response curves and fat absorption. J Lab Clin Med. 1953;42(5):700–704.
   Google Scholar
• Allegra S, De Francia S, Cusato J, et al. Deferasirox pharmacokinetic and toxicity correlation in β‐thalassaemia major treatment. J Pharm Pharmacol. 2016;68(11):1417–1421.
   Google Scholar
• Cusato J, Allegra S, De Francia S, et al. Role of pharmacogenetics on deferasirox AUC and efficacy. Pharmacogenomics. 2016;17(6):571–582.
   Google Scholar
• Chirnomas D, Smith AL, Braunstein J, et al. Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood. 2009;114(19):4009–4013.
   Google Scholar
• Lal A, Porter J, Sweeters N, et al. Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells Mol Dis. 2013;50(2):99–104.
   Google Scholar
• Sharma RN, Pancholi S. Oral iron chelators: A new avenue for the management of thalassemia major. J Curr Pharm Res. 2010;1:1–7.
   Google Scholar
• Xia S, Zhang W, Huang L, et al. Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials. PloS One. 2013;8(12):e82662.
   Google Scholar
• Eghbali A, Shokri PAfzal RR, et al. A 1-year randomized trial of deferasirox alone versus deferasirox and deferoxamine combination for the treatment of iron overload in thalassemia major. Transfus Apheresis Sci. 2019;58:429–433.
   Google Scholar
• Mattioli F, Puntoni M, Marini V, et al. Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy? Eur J Haematol. 2015;94(4):310–317.
   Google Scholar
• Galanello R, Piga A, Cappellini MD, et al. Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen. J Clin Pharmacol. 2008;48(4):428–435.
   Google Scholar
• Eghbali A, KhalilpourA, Taherahmadi H, et al. Pantoprazole reduces serum ferritin in patients with thalassemia major and intermedia: A randomized, controlled study. Therapie. 2019; 74(5):507–512.
   Google Scholar
• Wedemeyer R-S, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37(4):201–211.
   Google Scholar
• Kiley CA, Cragin DJ, Roth BJ. Omeprazole-associated digoxin toxicity. South Med J. 2007;100(4):400–403.
   Google Scholar
• Watanabe J, Sato K, Horiuchi T, et al. Elevated total iron-binding capacity as a predictor of response to deferasirox therapy in the setting of chronic iron overload. Int J Hematol. 2014;100(3):254–259.
   Google Scholar
• Zareifar S, Abdolkarimi B, Dehbozorgian J, Evaluation of omeprazole effect on iron overload in transfusion-dependent patients with thalassemia. Adv Biores. 2017;8(1):134-137.
   Google Scholar
• Gibaldi M, Koup J. Pharmacokinetic concepts—drug binding, apparent volume of distribution and clearance. Eur J Clin Pharmacol. 1981;20(4):299–305.
   Google Scholar
• Niece KL, Boyd NK, Akers KS. In vitro study of the variable effects of proton pump inhibitors on voriconazole. Antimicrob Agents Chemother. 2015;59(9):5548–5554.
   Google Scholar
• Marino ML, Fais S, Djavaheri-Mergny M, et al. Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells. Cell Death Dis. 2010;1:e87.
   Google Scholar
• Lan J, Jiang D. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J Neural Transm. 1997;104(4–5):469–481.
   Google Scholar
• Varma MV, Panchagnula R. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci. 2005;25(4–5):445–453.
   Google Scholar
• El-Ela FIA, El-Banna HA, El-Deen MB, et al. Pharmacokinetics of Tylvalosin alone or in combination with vitamin E in broiler chickens. Asian J Anim Vet Adv. 2015;10(10):556–566.
   Google Scholar
• Panachan J, Chokchaichamnankit D, Weeraphan C, et al. Differentially expressed plasma proteins of β-thalassemia/hemoglobin E patients in response to curcuminoids/vitamin E antioxidant cocktails. Hematology. 2019;24(1):300–307.
   Google Scholar
• Attia AMMSayed, IBRAHIM AM, et al. Effects of antioxidant vitamins on some hemoglobin properties and erythrocytes in homozygous beta-thalassemia. Rom J Biophys. 2011;21(1):116.
   Google Scholar
• Darvishi Khezri H, Salehifar E, Kosaryan M, et al. Potentialeffects of silymarin and its flavonolignan components in patients with β-thalassemia major: A comprehensive review in 2015. Adv Pharmacol Sci. 2016;2016:3046373–3046373.
   Google Scholar
• Šuk J, Jašprová J, Biedermann D, et al.Isolatedsilymarin flavonoids increase systemic and hepatic bilirubin concentrations and lower lipoperoxidation in mice. Oxid Med Cell Longev. 2019;2019:6026902.
   Google Scholar
• Bergman A, El-Kattan AF, Varma MV, et al. Projecting ADME behavior and drug-drug interactions in early discovery and development: application of the extended clearance classification system. Pharm Res. 2016;33(12):21–33.
   Google Scholar
• Han Y, Guo D, Chen Y, et al. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers. Xenobiotica. 2009;39(9):694–699.
   Google Scholar
• Voruganti S, Yamsani SK, Yamsani MR. Effect of silibinin on the pharmacokinetics of nitrendipine in rabbits. Eur J Drug Metab Pharmacokinet. 2014;39(4):277–281.
   Google Scholar
• Roozbeh J, Shahriyari B, Akmali M, et al.Comparative effects of silymarin and vitamin E supplementation on oxidative stress markers, and hemoglobin levels among patients on hemodialysis. Ren Fail. 2011;33(2):118–123
   Google Scholar
• Darvishi‐Khezri H, Salehifar E, Kosaryan M, et al. Iron‐chelating effect of silymarin in patients with β‐thalassemia major: A crossover randomised control trial. Phytother Res. 2018;32(3):496–503.
   Google Scholar